According to Porter et al., an annual clinical bone marrow evaluation is recommended only for children with CPSs with a greater risk for BMF and/or MDS/AML, including FA, familial AML with CEBPA mutations, SDS, severe congenital neutropenia, or GATA2 deficiency [57]. The gene discussed is CEBPA; the disease is myelodysplastic syndrome.